Recommended For You Cell Therapy Hair Treatment 12oz $56.95 New worth 9 loyalty points All Hair Types The unique micro-technology of the complex proteins in Cell Therapy penetrate the hair cortex, building strand strength from within. Use 2-3 times per week. Prepare hair by washing with an Ovation Hair Shampoo. Place a quarter to half dollar size amount (depending on hair length) of Ovation Cell Therapy in your palm. Massage into scalp and comb through to ends. Leave on for 3-5 minutes and rinse thoroughly. Follow with an Ovation Conditioner or Crme Rinse. Towel dry and style as desired. Testimonials What our customers are saying... I have noticed a tremendous difference in my hair. It is getting longer, and feels much thicker and looks healthier. I am amazed and love it. My sister uses it and raved about it, and ended up getting me a set of it for my birthday a year ago. I have been using it ever since. Lisa A. Ovation Hair Cell Therapy has worked miracles with my hair! It has significantly improved its texture and strength and reduced the amount lost with shampooing! Stephanie M. Very happy with Ovation Cell Therapy! Noticeabley healthier hair after … Continue reading →

Dive Brief: CAR-T therapy has already pushed the boundaries of what's possible in treating patients with certain types of aggressive blood cancers that are resistant to other treatments. The remarkable clinical efficacy seen in these patients, who would otherwise have few remaining options, stoked optimism that reprogramming T-cells to target and destroy cancers could transform the standard of care. That promise has led to heavy investment from biotech and pharma companies eager to become leaders in the still-emerging cell therapy space. Such investment has, in turn, created new market opportunities for companies that specialize in managing complex logistics and shipping networks. Cryoport, for example, has inked deals with both Novartis, Kite Pharma Inc. and several other cell therapy companies to help with cryopreservation of patient T-cells and what's known as chain-of-identity monitoring. Since most CAR-T therapies currently in development are made directly from a patient's own cells, companies need to ensure that reprogrammed cells are correctly matched and returned to the original patient. That requires the ability to identify a shipment of patient cells along every step of transport, from hospital through manufacturing and back to the same hospital again. Challenges like these add new risks and hurdles to the … Continue reading →

Adaptimmune Therapeutics, a leader in T-cell therapy to treat cancer, announced thatGlaxoSmithKline plc(LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmunes NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled for8:30 AM EDTthis morning; dial-in and webcast details are provided below. Adaptimmune will receive up to 48 million (~$61 million) from GSK over the course of the transition period. This includes development milestones of up to 18 million (~$23 million) and the option payment of 30 million (~$38 million), which also allows GSK to nominate two additional targets following completion of the transition. Successful continuation of development and subsequent commercialization of NY-ESO would trigger additional payments for development milestones, tiered sales milestones, and mid-single to low double-digit royalties on worldwide net sales. This is a very exciting day for Adaptimmune as GSK has exercised its option over our NY-ESO program, earlier than originally planned, commentedJames Noble, Chief Executive Officer at Adaptimmune. The commitment by one of the worlds leading pharmaceutical companies to the NY-ESO SPEAR T-cell program as a new treatment modality is a testament to the … Continue reading →

LONDON (Reuters) - French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment similar to Novartiss recently approved Kymriah, has been forced to suspend testing following a patient death. Cellectis said on Tuesday it was working closely with the U.S. Food and Drug Administration in order to resume trials with a lower dose of the medicine UCART123. Shares in the company fell 26 percent in morning trade following the U.S. regulators decision to place a so-called clinical hold on two early-stage trials of the medicine in blood cancers. Novartis made history last week when it won approval for its $475,000 drug Kymriah, the first in a new class of treatments called CAR-T immunotherapies that use modified disease-fighting T cells to attack cancer. While Novartis and rivals such as Juno and Kite use cells from the patients own body, Cellectiss gene edited cell therapy product offers an off-the-shelf, or allogeneic, option by deriving cells from healthy donors. It is designed to help patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). However, the first patient treated in the BPDCN study, a 78-year-old man, died after experiencing cytokine release syndrome (CRS), a dangerous release of cell-signaling … Continue reading →

Stem cell therapy is a two-step process. First, the patients blood cells are destroyed by chemotherapy, radiation therapy or immunosuppression. This conditioning process also eradicates any cancer cells that survived first-line treatment. Second, the patient receives stem cells harvested from a donors bone marrow or peripheral blood (circulating blood). While this can be an effective cure, it can cause graft-versus-host disease (GVHD) in up to 50% of patients. GVHD is more likely to develop in patients who have received a peripheral blood transplant and can kill 15%-20% of patients. Two types of GVHD can develop, acute and chronic, and patients may develop either one, both or neither type. GVHD is less likely to occur and symptoms are milder if the donor cells closely match those of the patient. Acute GVHD can develop within 100 days of a transplant. The first step of stem cell therapy can cause tissue damage, and bacteria from the gut can escape into the bloodstream. This primes the patients antigen-presenting cells (cells that activate the immune response), which subsequently encourage donor T cells to proliferate and attack the patients tissues. Symptoms include vomiting, diarrhea, skin rashes, nausea, vomiting and liver problems. This can be resolved relatively … Continue reading →

GE Healthcare has launched a thawing technology for cell therapies it says removes the risks and inconsistencies of standard water baths. Water bath thawing is the most common method for thawing cell therapies, Philip Vanek, GEs general manager of Cell Therapy Growth Strategy told Biopharma-Reporter. However, potential inconsistencies arise due to subjective determination of the thaw endpoint and risk of water-borne contamination, at the very point where the product is most valuable and most vulnerable. There is no easy way to record what is happening to a sample which makes it hard to know if procedures are all being followed identically, he continued, adding the process is labour-intensive, requiring staff to regularly complete contamination control procedures. Therefore the firm has launched the VIA Thaw CB1000, an automated platform for the dry thawing of cryo-bags which Vanek told us overcomes these problems. VIA Thaw constantly monitors the sample temperature across multiple locations, records everything that happens in a comprehensive log and even takes a photo of the thawed therapy to prove it has been correctly handled. Furthermore, the system requires no specialist skills to operate and delivers high recoveries of viable cells. Blossoming space The personalised medicine space is just beginning … Continue reading →

Spain has licensed TiGenix NV's expanded Madrid plant paving the way for a potential European launch of Cx601, its cell therapy forthe Crohn's disease complications. Belgium-based TiGenix announced it received the Spanish Medicines Agency (AEMPS) license this week, explaining the Madrid plant will provide capacity for production of its portfolio of cell therapies including the candidate cell therapy Cx601. Chief technical officer Wilfried Dalemans said: We have now significantly increased our manufacturing capacity, a key step in the preparation for commercialization of Cx601 in Europe and in the further development of our pipeline. Cx601 has been accepted for review by the European Medicines Agency (EMA) and Swissmedic, which began reviewing TiGenix dossier in June. At the time the firm told us Takeda will take over responsibility for making the cell therapy from 2021 but did not provide additional details. Manufacturing expansion Cx601 is made from stem cells taken from donor adipose tissue. It is being developed for the treatment of complex perianal fistulas in patients with Crohns disease patients who do not otherwise respond to standard therapies. The therapy is madein a 2-dimensional cell culture. TiGenix expanded the Madrid facility with support from Japanese drug firm Takeda, which licensed rights … Continue reading →